Search Results
Your search for ,mBa matches 871 pages
Showing 1 - 50ASCO Names 2025 Q1, Q2 FASCO Recipients
Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction honors members for their extraordinary volunteer service, engagement, and dedication to American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO). Listed here are the FASCO ...
OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight
Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally. It is the largest single donation ever made to a ...
Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC
Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible. The guidelines, published in the journal CHEST,...
STRIDE in Unresectable HCC: 5-Year Overall Survival Results From HIMALAYA
A recent exploratory analysis of the phase III HIMALAYA trial involving patients with unresectable hepatocellular carcinoma (HCC) has shown that 1 in 5 participants (19.6%) treated with the STRIDE regimen (single tremelimumab regular interval durvalumab) remained alive after 5 years of follow-up vs ...
ASTRO Announces New President-Elect, Officers
The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors: Catheryn M. Yashar, MD, FASTRO, President-Elect Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair...
American Cancer Society Names New CEO
The American Cancer Society (ACS) and its advocacy affiliate the American Cancer Society Cancer Action Network (ACS CAN) have announced Shane Jacobson as their Chief Executive Officer, effective August 12, 2025. He steps into the role following Wayne A.I. Frederick, MD, MBA, FACS, who has served as ...
Extended Follow-up for Neoadjuvant and Adjuvant Relatlimab Plus Nivolumab in Resectable Melanoma
In an extended follow-up of a phase II trial reported in the Journal of Clinical Oncology, Burton et al examined outcomes with neoadjuvant and adjuvant relatlimab-rmbw plus nivolumab in patients with resectable melanoma. Relatlimab targets LAG3, while nivolumab targets PD-1. Study Details In the...
Studies Explore Cardiac Risks and Clinical Characteristics Associated With Immune Checkpoint Inhibitor–Related Myocarditis
Immune checkpoint inhibitors (ICIs) have significantly impacted treatment options for a wide range of cancers given their efficacy, especially among cancer types that are considered immunologically “hot.” With this broad benefit across many tumor types, researchers continue to look for ways to...
The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology
Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this position on August 15. Dr. Rolfo will ...
Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035
The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS). The...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award
Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....
New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma
The first individualized risk prediction model for adults with early-stage classical Hodgkin lymphoma (cHL) has been developed and validated. According to a report published in NEJM Evidence, the Early-Stage cHL International Prognostic Index (E-HIPI) model estimates 2-year progression-free...
Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating...
ASCO Congratulates 2025 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2025 ASCO Annual Meeting. “The recipients of this year’s...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
A High Proportion of U.S. Adults Are Behind on Cancer Screenings
Investigators have found that a large proportion of U.S. adults are behind on their cancer screenings, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Methods and Findings In the Survivor Views Special Report: National Screening Survey,...
2025 ACS Cancer Prevention, Early Detection Report: Cancer Screening Rates, Modifiable Risk Factors
Investigators have uncovered mixed progress in major cancer risk factors, preventive behaviors, and screenings in the post–COVID-19 pandemic period among adults in the United States, according to a new study published by Bandi et al in Cancer Epidemiology, Biomarkers & Prevention. Background An ...
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Hyperefficient and Super-Digitized Health Care: Where Is the Smile?
A few weeks ago, a family member underwent a minor outpatient operative procedure. From a few weeks before the scheduled date of the procedure, multiple text messages and e-mails were forwarded to provide preparatory instructions for the procedure. The day before the procedure, another...
Is This the End of Cancer Research as We Know It?
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw made its way to facilities and administrative (F&A)...
Medicare Claim Denials for Cancer-Related NGS Testing Show Uncertainty of Coverage
More than 20% of cancer-related claims for next-generation sequencing (NGS) from Medicare beneficiaries were denied between 2016 and 2021. Findings from a cohort study published in JAMA Network Open suggested that there is continued uncertainty about the boundaries of coverage for NGS, even with...
Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases
Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...
Study Illuminates Disparities in Treatment, Survival in Metastatic Pancreatic Ductal Adenocarcinoma
Investigators may have uncovered factors that may impact the quality of cancer care and outcomes among patients with metastatic pancreatic ductal adenocarcinoma, according to a recent study published by Tsilimigras et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods...
American Cancer Society Launches CEO Search
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) announced the launch of a nationwide search to find the organizations’ next Chief Executive Officer (CEO). In November, the ACS Board of Directors appointed Wayne A.I. Frederick, MD, MBA, to serve as...
Awareness of Alcohol-Related Cancer Risks May Be Growing
An increasing proportion of the U.S. public may be aware of the link between consuming alcohol and the elevated risk of later developing cancer, according to a recent survey conducted by the University of Pennsylvania’s Annenberg Public Policy Center (APPC). Background On January 3, 2025, Vivek...
Smoking Status of the U.S. Cancer Population
In a study reported as a research letter in JAMA Oncology, Caturegli et al attempted to identify smoking status of patients diagnosed with cancer in the United States in 2023. Study Details In the cross-sectional study, the smoking status of patients diagnosed with cancer in 2023 was collected by...
Parker Institute for Cancer Immunotherapy Names New CEO
The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...
Tobacco Control May Have Prevented Millions of Premature Lung Cancer Deaths in United States
Tobacco control–driven reductions in smoking prevalence may have helped avert over 3.8 million lung cancer–related deaths and gain just over 76 million years of life between 1970 and 2022 in the United States, according to a recent study published by Islami et al in CA: A Cancer Journal for...
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.” —Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment
Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
New Study Uncovers Low Uptake of Supportive Care at End of Life in Patients With Advanced Cancer
Investigators have found that nearly 50% of patients with advanced cancer may receive potentially aggressive treatment at the expense of supportive care, despite considerable efforts to improve the quality of end-of-life care in the United States, according to a recent study published by Kwon et al ...
Cancer Mortality Rates Among Black Patients vs Other Racial, Ethnic Groups
Although the cancer mortality rate among Black patients in the United States has dropped over the past 30 years, this patient population may continue to experience a disproportionately elevated cancer burden compared with other patient populations, according to a recent study published by Saka et...
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Cancer Mortality Rates Continue to Decline, Incidence Rates in Women Rise, and Racial Disparities Persist
The findings in the American Cancer Society (ACS) annual report, Cancer Statistics, 2025,1 showed a mixed trend in cancer incidence and mortality rates. Although cancer mortality declined by 34% from 1991 to 2022 in the United States—largely because of smoking reductions, earlier detection, and...
Jennifer A. Woyach, MD, Named The Ohio State’s Director of Hematology
Jennifer A. Woyach, MD, a hematology cancer expert and researcher who has been with The Ohio State for more than 12 years, has been named Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
Intratumoral Injection of mRNA-2752 and Pembrolizumab in High-Risk DCIS
In a single-institution phase I trial reported in JAMA Oncology, Ramalingam et al found that intratumoral injection of pembrolizumab and mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs) was active in patients with high-risk ductal carcinoma in situ (DCIS). Study Details Ten ...
Weight Change and Heart Failure Risk After Breast Cancer Diagnosis
In a Republic of Korea nationwide cohort study reported as a research letter in JAMA Oncology, Jung et al found that weight increase following diagnosis of breast cancer was associated with increased risk of heart failure. Study Details The study used the National Health Insurance Service database...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
UICC, ICCP: Landmark Review of National Cancer Strategies Illuminates Progress, Persistent Challenges
The Union for International Cancer Control (UICC) has examined the National Cancer Control Plans and reported their findings in a new comprehensive global review published by Romero et al in The Lancet Oncology. The findings will be presented at the Cancer Planners Forum in May 2025 in Geneva,...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cameroon
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cameroon. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma
In the phase III CEPHEUS trial,1 the achievement of undetectable measurable residual disease (or MRD negativity)—the primary endpoint—was met by 61% of patients with transplant-ineligible or deferred newly diagnosed multiple myeloma treated with the monoclonal antibody daratumumab plus bortezomib, ...
FDA Approves Oral Liquid Imatinib to Treat Patients With Leukemia and Other Cancer Types
The U.S. Food and Drug Administration (FDA) announced the approval of imatinib (Imkeldi) oral solution, the first oral liquid formulation of the drug to treat certain types of leukemias and other cancers. Background In 2024, an estimated 9,280 patients will be diagnosed with chronic myeloid...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
FDA Approves Novel Companion Diagnostic Assay
Caris Life Sciences announced that the U.S. Food and Drug Administration (FDA) has approved MI Cancer Seek for use as a companion diagnostic assay to identify patients with cancer who may benefit from targeted therapies. Caris Life Sciences is a next-generation artificial intelligence techbio...
From Gaps to Bridges: Cancer Care Rooted in Equity, Quality, and Value
“Inequities are a major obstacle in delivering safe, timely, respectful, and affordable cancer care globally,” commented moderator John Varallo, MD, MPH, FACOG, of the Global Surgery Foundation, at the Union for International Cancer Control (UICC) World Cancer Congress (WCC) 2024 in Geneva.1...
18 Researchers and Mentors Selected for ASCO’s Inaugural International Clinical Research Scholars Program in Latin America
ASCO has announced the participants and mentors selected for its new International Clinical Research Scholars (ICR) program. Eighteen scholars were selected by the ASCO Latin America Regional Council to take part in this 1-year program that pairs clinical research training with mentorship...
$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities
Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb...
Medicaid Expansion May Improve Cancer Care, Survival Among Patients With Hormone Receptor–Negative, HER2-Positive Breast Cancer
Patients with newly diagnosed hormone receptor–negative, HER2-positive breast cancer were more likely to receive timely, guideline-concordant treatment and experience longer survival in states participating in Medicaid expansion under the Affordable Care Act, according to a recent study published...
